

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-9. (canceled).

10. (currently amended): A pharmaceutical composition of solifenacin or a salt thereof for use in a solid formulation, the composition containing crystalline and amorphous solifenacin or a crystalline and amorphous salt thereof, together with an inhibitor of an amorphous preparation, wherein the inhibitor of an amorphous preparation is a substance having an ethylene oxide chain and wherein the crystalline and amorphous solifenacin or a crystalline and amorphous salt thereof is not in contact with or in mixture with the inhibitor of an amorphous preparation (excluding using the inhibitor of an amorphous preparation as a coating agent).

11. (canceled).

12. (previously presented): A pharmaceutical composition according to claim 17, wherein the substance having an ethylene oxide chain is polyethylene glycol.

13-16. (canceled).

17. (previously presented): The pharmaceutical composition according to claim 10, wherein the substance having an ethylene oxide chain is polyethylene glycol, polyethylene oxide, polyoxyethylene polyoxypropylene block copolymer, polyoxyethylene hardened castor oil, or polyethylene glycol fatty acid ester.